ArticleInternational journal of ophthalmology2025
GPR120/FFAR4 protects retinal vascular endothelial cells against high glucose injury
Article in International journal of ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting endoplasmic reticulum stress in diabetic retinopathy: mechanistic insights and emerging therapies.Biological research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo evaluate the role of reactive oxygen species-endoplasmic reticulum stress (ROS-ERS) in the cellular protection of G protein-coupled receptor 120 (GPR120/FFAR4) against high glucose (HG) induced human retinal vascular endothelial cell (HRVEC) injury and its underlying mechanisms.
methodsHRVECs were divided into the control group, GW9508 (an agonist of GPR120) group, HG group, and HG+GW9508 group. The cell proliferation and apoptosis were assessed by cell counting kit-8 and annexin V-FITC/PI apoptosis detection kit, respectively. Western blotting analysis was performed to assess the protein expressions of Bax, Bcl-2, activating transcription factor 6 (ATF6), PKR-like endoplasmic reticulum kinase (PERK), and inositol-requiring enzyme 1 (IRE1). The ROS assay kit was used for the detection of ROS production. Then the cells were transfected with siRNA of GPR120 and the ROS level and protein levels of ATF6, PERK, and IER1 were compared.
resultsGW9508 promoted the proliferation of HRVECs, which was significantly reduced by the stimulation of HG. GW9508 remarkably reduced the apoptosis rate of HRVECs under HG and the expression of proapoptotic protein Bax, while increased the expression of antiapoptotic protein Bcl-2. Under HG condition, a significant increase of ROS production was noticed in HRVECs, and GW9508 treatment greatly decreased it. The over-expressions of ERS-related proteins ATF6, PERK, and IER1 under HG were down-regulated by GW9508 treatment. After successfully transfected with siGPR120, the effects of GW9508 on the production of ROS as well as the expressions of ATF6, PERK, and IER1 were reversed.
conclusionGPR120 protects HRVECs against HG induced apoptosis, and suppressing ROS-ERS pathway is one of the mechanisms involved. Activation of GPR120 may be considered as a potential therapeutic target for diabetic retinopathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.